203 related articles for article (PubMed ID: 2031968)
1. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters.
Nachbaur DM; Herold M; Maneschg A; Huber H
Ann Hematol; 1991; 62(2-3):54-8. PubMed ID: 2031968
[TBL] [Abstract][Full Text] [Related]
2. Multiple myeloma: an immunoclinical study of disease and response to treatment.
Thavasu PW; Ganjoo RK; Maidment SA; Love SB; Williams AH; Malplas JS; Balkwill FR
Hematol Oncol; 1995; 13(2):69-82. PubMed ID: 7797195
[TBL] [Abstract][Full Text] [Related]
3. Increased serum neopterin concentration as indicator of disease severity and poor survival in multiple myeloma.
Boccadoro M; Battaglio S; Omedè P; Palumbo AP; Fusaro A; Frieri R; Gallone G; Polloni R; Mosso R; De Filippi PG
Eur J Haematol; 1991 Oct; 47(4):305-9. PubMed ID: 1954991
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of serum IL-6 level in monoclonal gammopathies.
DuVillard L; Guiguet M; Casasnovas RO; Caillot D; Monnier-Zeller V; Bernard A; Guy H; Solary E
Br J Haematol; 1995 Feb; 89(2):243-9. PubMed ID: 7873373
[TBL] [Abstract][Full Text] [Related]
5. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913
[TBL] [Abstract][Full Text] [Related]
6. Serum neopterin and beta 2-microglobulin concentrations in monoclonal gammopathies.
Fine JM; Lambin P; Desjobert H
Acta Med Scand; 1988; 224(2):179-82. PubMed ID: 3048055
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.
Bataille R; Jourdan M; Zhang XG; Klein B
J Clin Invest; 1989 Dec; 84(6):2008-11. PubMed ID: 2592570
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma.
Solary E; Guiguet M; Zeller V; Casasnovas RO; Caillot D; Chavanet P; Guy H; Mack G
Am J Hematol; 1992 Mar; 39(3):163-71. PubMed ID: 1546713
[TBL] [Abstract][Full Text] [Related]
9. High serum interleukin-2 levels in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma.
Cimino G; Avvisati G; Amadori S; Di Gregorio AO; Magliocca V; Petrucci MT; Sgadari C
Nouv Rev Fr Hematol (1978); 1989; 31(5):329-32. PubMed ID: 2587201
[TBL] [Abstract][Full Text] [Related]
10. Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma.
Filella X; Blade J; Guillermo AL; Molina R; Rozman C; Ballesta AM
Cancer Detect Prev; 1996; 20(1):52-6. PubMed ID: 8907203
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of interleukin-6 and neopterin in patients with multiple myeloma.
Reibnegger G; Krainer M; Herold M; Ludwig H; Wachter H; Huber H
Cancer Res; 1991 Dec; 51(23 Pt 1):6250-3. PubMed ID: 1933885
[TBL] [Abstract][Full Text] [Related]
12. Different lymphoid cell populations produce varied levels of neopterin, beta 2-microglobulin and soluble IL-2 receptor when stimulated with IL-2, interferon-gamma or tumour necrosis factor-alpha.
Hofmann B; Bass H; Nishanian P; Faisal M; Figlin RA; Sarna GP; Fahey JL
Clin Exp Immunol; 1992 Jun; 88(3):548-54. PubMed ID: 1606739
[TBL] [Abstract][Full Text] [Related]
13. Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma.
Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):3025-9. PubMed ID: 9329592
[TBL] [Abstract][Full Text] [Related]
14. Serum soluble tumour necrosis factor receptor 55 is increased in patients with haematological neoplasias and is associated with immune activation and weight loss.
Denz H; Orth B; Weiss G; Gallati H; Herrmann R; Huber P; Wachter H; Fuchs D
Eur J Cancer; 1993; 29A(16):2232-5. PubMed ID: 8110491
[TBL] [Abstract][Full Text] [Related]
15. Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease.
Seymour JF; Talpaz M; Hagemeister FB; Cabanillas F; Kurzrock R
Am J Med; 1997 Jan; 102(1):21-8. PubMed ID: 9209197
[TBL] [Abstract][Full Text] [Related]
16. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma.
Legouffe E; Rodriguez C; Picot MC; Richard B; Klein B; Rossi JF; Commes T
Leuk Lymphoma; 1998 Oct; 31(3-4):351-7. PubMed ID: 9869199
[TBL] [Abstract][Full Text] [Related]
17. Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanoma.
Liebes L; Walsh CM; Chachoua A; Oratz R; Richards D; Hochster H; Peace D; Marino D; Alba S; Le Sher D
J Natl Cancer Inst; 1992 May; 84(9):694-9. PubMed ID: 1569602
[TBL] [Abstract][Full Text] [Related]
18. Correlation and prognostic value of serum soluble ICAM-1, beta-2 microglobulin, and IL-2alphaR levels in non-Hodgkin's lymphoma.
Pérez-Encinas M; Quintas A; Bendaña A; Rabuñal MJ; Bello JL
Leuk Lymphoma; 1999 May; 33(5-6):551-8. PubMed ID: 10342582
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity.
Papadaki H; Kyriakou D; Foudoulakis A; Markidou F; Alexandrakis M; Eliopoulos GD
Acta Haematol; 1997; 97(4):191-5. PubMed ID: 9158660
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of serum levels of Dickkopf-1 (DKK-1) in monoclonal gammopathy of undetermined significance and multiple myeloma].
Ščudla V; Petrová P; Pika T; Lochman P; Minařík J; Bačovský J; Srovnalík K
Cas Lek Cesk; 2015; 154(4):181-8. PubMed ID: 26357861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
